

# N-TENSE



120 capsules (700 mg each)

Retail Price: \$29.95

A combination of 8 plants which have been independently documented around the world with active biological actions.\* For more complete information on these unique rainforest plant ingredients, please see the Raintree Nutrition internet website and the online [Tropical Plant Database](#).

**Ingredients:** A proprietary blend of graviola, mullaca, guacatonga, espinheira santa, bitter melon, vassourinha, mutamba, and cat's claw.

**Suggested Use:** Take 3-4 capsules three times daily.

## Contraindications:

- Not to be used during pregnancy or while breast-feeding.
- Several ingredients in this formula have demonstrated hypotensive, vasodilator, and cardiodepressant activities in animal studies. People with low blood pressure should monitor their blood pressure for this possible effect.

**Drug Interactions:** This product may enhance or increase the effect of high blood pressure drugs.

## Other Practitioner Observations:

- Several ingredients in this formula have demonstrated significant in vitro antimicrobial properties. Supplementing the diet with probiotics (like acidophilus found in live-cultured yogurt) is advisable when this product is used for longer than 30 days.
- Taking CoQ10 and other supplements which increase cellular ATP might reduce the effects of N-Tense.

**Clinical Documentation and Research:**\* This proprietary Raintree product has not been the subject of any clinical research. Available third-party published research on each ingredient in this formula can be found at the Raintree website. A partial listing of published research on these ingredients is shown below:

### [Graviola \(\*Annona muricata\*\)](#)

- Kojima, N. "Systematic synthesis of antitumor Annonaceous acetogenins" *Yakugaku Zasshi*. 2004; 124(10): 673-81.
- Tormo, J. R., et al. "In vitro antitumor structure-activity relationships of threo/trans/threo mono-tetrahydro-furanic acetogenins: Correlations with their inhibition of mitochondrial complex I." *Oncol. Res.* 2003; 14(3): 147-54.
- Yuan, S. S., et al. "Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax- and caspase-3-related pathway." *Life Sci.* 2003 May; 72(25): 2853-61.
- Liaw, C. C., et al. "New cytotoxic monotetrahydrofuran Annonaceous acetogenins from *Annona muricata*." *J. Nat. Prod.* 2002; 65(4): 470-75.
- Gonzalez-Coloma, A., et al. "Selective action of acetogenin mitochondrial complex I inhibitors." *Z. Naturforsch.* 2002; 57(11-12): 1028-34.
- Chang, F. R., et al. "Novel cytotoxic Annonaceous acetogenins from *Annona muricata*." *J. Nat. Prod.* 2001; 64(7): 925-31.
- Jaramillo, M., et al. "Cytotoxicity and antileishmanial activity of *Annona muricata* pericarp." *Fitoterapia.* 2000; 71 (2): 183-6.
- Betancur-Galvis, L., et al. "Antitumor and antiviral activity of Colombian medicinal plant extracts." *Mem. Inst. Oswaldo Cruz.* 1999; 94(4): 531-35.
- Kim, G. S., et al. "Muricoreacin and murihexocin C, mono-tetrahydrofuran acetogenins, from the leaves of *Annona muricata*." *Phytochemistry.* 1998; 49(2): 565-71.
- Kim, G. S., et al. "Two new mono-tetrahydrofuran ring acetogenins, anomuricin E and muricapentocin, from the leaves of *Annona muricata*." *J. Nat. Prod.* 1998; 61(4): 432-36.
- Nicolas, H., et al. "Structure-activity relationships of diverse Annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells." *J. Med. Chem.* 1997; 40(13): 2102-6.
- Zeng, L., et al. "Five new monotetrahydrofuran ring acetogenins from the leaves of *Annona muricata*." *J. Nat. Prod.* 1996; 59(11): 1035-42.
- Wu, F. E., et al. "Two new cytotoxic monotetrahydrofuran Annonaceous acetogenins, anomuricins A and B, from the leaves of *Annona muricata*." *J. Nat. Prod.* 1995; 58(6): 830-36.
- Oberlies, N. H., et al. "Tumor cell growth inhibition by several Annonaceous acetogenins in an *in vitro* disk diffusion assay." *Cancer Lett.* 1995; 96(1): 55-62.
- Wu, F. E., et al. "Additional bioactive acetogenins, anomutacin and (2,4-trans and cis)-10R-annonacin-A-ones, from the leaves of *Annona muricata*." *J. Nat. Prod.* 1995; 58(9): 1430-37.
- Wu, F. E., et al. "New bioactive monotetrahydrofuran Annonaceous acetogenins, anomuricin C and muricatocin C, from the

leaves of *Annona muricata*." *J. Nat. Prod.* 1995; 58(6): 909-5.

Wu, F. E., et al. "Muricatocins A and B, two new bioactive monotetrahydrofuran Annonaceous acetogenins from the leaves of *Annona muricata*." *J. Nat. Prod.* 1995; 58(6): 902-8.

### Mullaca (*Physalis angulata*)

Ausseil, F., et al. "High-throughput bioluminescence screening of ubiquitin-proteasome pathway inhibitors from chemical and natural sources." *J. Biomol. Screen.* 2006 Dec 14;

Kuo, P. C., et al. "Physanolide A, a novel skeleton steroid, and other cytotoxic principles from *Physalis angulata*." *Org. Lett.* 2006 Jul; 8(14): 2953-6.

Ichikawa, H., et al. "Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression." *Mol. Cancer Ther.* 2006; 5(6): 1434-45.

Magalhaes, H. I., et al. "In-vitro and in-vivo antitumor activity of physalins B and D from *Physalis angulata*." *J. Pharm. Pharmacol.* 2006; 58(2): 235-41.

Jacobo-Herrera, N. J., et al. "Physalins from *Witheringia solanacea* as modulators of the NF-kappaB cascade." *J. Nat. Prod.* 2006; 69(3): 328-31.

Hsieh, W. T., et al. "*Physalis angulata* induced G2/M phase arrest in human breast cancer cells." *Food Chem Toxicol.* 2006; 44(7): 974-83.

Lee, C. C., et al. "Cytotoxicity of plants from Malaysia and Thailand used traditionally to treat cancer." *J. Ethnopharmacol.* 2005 Sep; 100(3): 237-43.

Wu, S. J., et al. "Antihepatoma activity of *Physalis angulata* and *P. peruviana* extracts and their effects on apoptosis in human Hep G2 cells." *Life Sci.* 2004 Mar; 74(16): 2061-73.

Leyon, P. V., et al. "Effect of *Withania somnifera* on B16F-10 melanoma induced metastasis in mice." *Phytother. Res.* 2004; 18(2): 118-22.

Kawai, M., et al. "Cytotoxic activity of physalins and related compounds against HeLa cells." *Pharmazie* 2002; 57(5): 348-50.

Ismail, N., et al. "A novel cytotoxic flavonoid glycoside from *Physalis angulata*." *Fitoterapia.* 2001 Aug. 72(6): 676-79.

Lee, Y. C., et al. "Integrity of intermediate filaments is associated with the development of acquired thermotolerance in 9L rat brain tumor cells." *J. Cell. Biochem.* 1995; 57(1): 150-62.

Perng, M. D., et al. "Induction of aggregation and augmentation of protein kinase-mediated phosphorylation of purified vimentin intermediate filaments by withangulatin A." *Mol. Pharmacol.* 1994; 46(4): 612-17.

Chiang, H., et al. "Antitumor agent, physalin F from *Physalis angulata* L." *Anticancer Res.* 1992; 12(3): 837-43.

Chiang, H. et al. "Inhibitory effects of physalin B and physalin F on various human leukemia cells in vitro." *Anticancer Res.* 1992; 12(4): 1155-62.

Kusumoto, I., et al. "Inhibitory effect of Indonesian plant extracts on reverse transcriptase of an RNA tumour virus (I)." *Phytother. Res.* 1992; 6(5): 241-44.

Lee, W. C., et al. "Induction of heat-shock response and alterations of protein phosphorylation by a novel topoisomerase II inhibitor, withangulatin A, in 9L rat brain tumor cells." *Cell Physiol.* 1991; 149(1): 66-67.

Chen, C. M., et al. "Withangulatin A, a new withanolide from *Physalis angulata*." *Heterocycles.* 1990; 31(7): 1371-75.

Basey, K., et al. "Phygrine, an alkaloid from *Physalis* species." *Phytochemistry.* 1992; 31(12): 4173-76.

Juang, J. K., et al. "A new compound, withangulatin A, promotes type II DNA topoisomerase mediated DNA damage." *Biochem. Biophys. Res. Commun.* 1989; 159(3): 1128-34.

Anon. "Biological assay of antitumor agents from natural products." Abstr.: Seminar on the Development of Drugs from Medicinal Plants Organized by the Department of Medical Science Department at Thai Farmer Bank, Bangkok, Thailand 1982; 129.

Antoun, M. D., et al. "Potential antitumor agents. XVII. physalin B and 25,26-epidihydrophysalin C from *Witheringia coccoloboides*." *J. Nat. Prod.* 1981; 44(5): 579-85.

### Guacatonga (*Casearia sylvestris*)

Balunas, M. J., et al. "Relationships between inhibitory activity against a cancer cell line panel, profiles of plants collected, and compound classes isolated in an anticancer drug discovery project." *Chem. Biodivers.* 2006; 3(8): 897-915.

Shen, Y. C., et al. "Cytotoxic clerodane diterpenoids from *Casearia membranacea*." *J. Nat. Prod.* 2005; 68(11): 1665-8.

Maistro, E. L., et al. "Evaluation of the genotoxic potential of the *Casearia sylvestris* extract on HTC and V79 cells by the comet assay." *Toxicol. In Vitro.* 2004 Jun; 18(3): 337-42.

Oberlies, N. H., et al. "Novel bioactive clerodane diterpenoids from the leaves and twigs of *Casearia sylvestris*." *J. Nat. Prod.* 2002; 65(2): 95-99.

Sai Prakash, C. V., et al. "Structure and stereochemistry of new cytotoxic clerodane diterpenoids from the bark of *Casearia lucida* from the Madagascar rainforest." *J. Nat. Prod.* 2002; 65(2): 100-7.

Beutler, J. A. "Novel cytotoxic diterpenes from *Casearia arborea*." *J. Nat. Prod.* 2000; 63(5): 657-61.

Almeida, A. "Antitumor and anti-inflammatory effects of extract from *Casearia sylvestris*: comparative study with Piroxicam and Meloxicam." Instituto de Ciencias Biomedicas, University of Sao Paulo (Dissertation, 4/02/99).

Itokawa, H., et al. "Antitumor substances from South American plants." *J. Pharmacobio. Dyn.* 1992; 15(1): S-2-.

Morita, H., et al. "Structures and cytotoxic activity relationship of casearins, new clerodane diterpenes from *Casearia sylvestris*

Sw." *Chem. Pharm. Bull.* (Tokyo) 1991 Dec; 39(3): 693–97.

Itokawa, H., et al. "New antitumor principles, casearins A–F, for *Casearia sylvestris* Sw. (Flacourtiaceae)." *Chem. Pharm. Bull.* (Tokyo) 1990; 38(12): 3384–88.

Itokawa, H., et al. "Isolation of diterpenes as antitumor agents from plants." Patent—Japan Kokai Tokyo Koho–01 1989; 149, 779: 6pp.

Itokawa, H., et al. "Antitumor principles from *Casearia sylvestris* Sw. (Flacourtiaceae), structure elucidation of new clerodane diterpenes by 2-D NMR spectroscopy." *Chem. Pharm. Bull.* (Tokyo) 1988 March; 36(4): 1585–88.

### **Espinheira Santa (*Maytenus ilicifolia*)**

Liu Z, et al. "Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry." *J. Mass. Spectrom.* 2005; 40(3): 389-99.

Nakao, H., et al. "Cytotoxic activity of maytanprine isolated from *Maytenus diversifolia* in human leukemia K562 cells." *Biol. Pharm. Bull.* 2004; 27(8): 1236-40.

Cassady, J. M., et al. "Recent developments in the maytansinoid antitumor agents." *Chem. Pharm. Bull.* 2004; 52(1): 1-26.

Ohsaki, A., et al. "Four new triterpenoids from *Maytenus ilicifolia*." *J. Nat. Prod.* 2004; 67(3): 469-71.

Horn, R. C., et al. "Antimutagenic activity of extracts of natural substances in the Salmonella/microsome assay." *Mutagenesis.* 2003 Mar; 18(2): 113-8.

Buffa Filho, W., et al. "Quantitative determination for cytotoxic Friedo-nor-oleanane derivatives from five morphological types of *Maytenus ilicifolia* (Celastraceae) by reverse-phase high-performance liquid chromatography." *Phytochem. Anal.* 2002 Mar-Apr; 13(2): 75-8.

Miura, N. et al. "Protective effects of triterpene compounds against the cytotoxicity of cadmium in HepG2 cells." *Mol. Pharm.* 1999; 56(6): 1324–28.

Liu, C., et al. "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids." *Proc. Natl. Acad. Sci.* 1996 Aug; 93(16): 8618-23.

Shirota, O., et al. "Cytotoxic aromatic triterpenes from *Maytenus ilicifolia* and *Maytenus chuchuhuasca*." *J. Nat. Prod.* 1994; 57(12): 1675–81.

Itokawa, H., et al. "Cangorins F–J, five additional oligo-nicotinated sesquiterpene polyesters from *Maytenus ilicifolia*." *J. Nat. Prod.* 1994; 57(4): 460–70.

Arisawa, M., et al. "Cell growth inhibition of KB cells by plant extracts." *Natural Med.* 1994; 48(4): 338–347.

Itokawa, H., et al. "Oligo-nicotinated sesquiterpene polyesters from *Maytenus ilicifolia*." *J. Nat. Prod.* 1993; 56(9): 1479–1485.

Itokawa, H., et al. "Antitumor substances from South American plants." *Pharmacobio. Dyn.* 1992; 15(1): S

Fox, B. W. "Medicinal plants in tropical medicine. 2. Natural products in cancer treatment from bench to the clinic." *Trans. R. Soc. Trop. Med. Hyg.* 1991; 85(1): 22-5.

Ravry, M. J., et al. "Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial." *Am. J. Clin. Oncol.* 1985 Apr; 8(2): 148-50.

Suffnes, M. J., et al. "Current status of the NCI plant and animal product program." *J. Nat. Prod.* 1982; 45: 1–14.

Cabanillas, F., et al. "Phase I study of maytansine using a 3-day schedule." *Cancer Treatment Reports.* 1976; (60): 1127–39.

Chabner, B. A., et al. "Initial clinical trials of mayansine, an antitumor plant alkaloid." *Cancer Treatment Reports.* 1978; (62): 429–33.

O'Connell, M. J., et al. "Phase II trial of maytansine in patients with advanced colorectal carcinoma." *Cancer Treatment Reports.* 1978 (62); 1237-38.

Wolpert-Defillipes, M. K., et al. "Initial studies on the cytotoxic action of maytansine, a novel ansa macrolide." *Biochemical Pharmacology.* 1975; 24: 751–54.

Melo, A. M., et al. "First observations on the topical use of primin, plumbagin and maytenin in patients with skin cancer." *Rev. Inst. Antibiot.* 1974 Dec.

Monache, F. D., et al., "Maitenin: A new antitumoral substance from *Maytenus sp.*" *Gazetta Chimica Italiana* 1972; 102: 317–20.

de Santana, C. F., et al. "Primeiras observacoes sobre o emprego da maitenina em pacientes cancerosos." *Rev. Inst. Antibiot.* 1971; 11: 37–49.

Hartwell, J. L. "Plants used against cancer: A survey." *Lloydia.* 1968; 31: 114.

### **Bitter Melon (*Momordica charantia*)**

Hwang, Y., et al. "Momordin I, an inhibitor of AP-1, suppressed osteoclastogenesis through inhibition of NF-kappaB and AP-1 and also reduced osteoclast activity and survival." *Biochem. Biophys. Res. Commun.* 2005 Nov; 337(3): 815-23.

Yasui, Y., et al. "Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells." *Prostaglandins Leukot. Essent. Fatty Acids.* 2005 Aug; 73(2): 113-9.

Ike, K., et al. "Induction of interferon-gamma (IFN-gamma) and T helper 1 (Th1) immune response by bitter gourd extract." *J. Vet. Med. Sci.* 2005; 67(5): 521-4.

Nagasawa, H., et al. "Effects of bitter melon (*Momordica charantia*) or ginger rhizome (*Zingiber officinale* Rosc.) on spontaneous mammary tumorigenesis in SHN mice." *Am. J. Clin. Med.* 2002; 30(2–3): 195–205.

Kim, J. H., et al. "Induction of apoptosis by momordin I in promyelocytic leukemia (HL-60) cells." *Anticancer Res.* 2002

May-Jun; 22(3): 1885-9.

Tazzari, P. L., et al. "An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins." *Haematologica*. 1999; 84(11): 988-95.

Lee, D. K., et al. "Momordins inhibit both AP-1 function and cell proliferation." *Anticancer Res*. 1998 Jan-Feb; 18(1A): 119-24.

Terenzi, A., et al. "Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumor activity against CD30+ tumor cells in vitro and in SCID mice." *Br. J. Haematol*. 1996; 92(4): 872-79.

Bolognesi, A., et al. "Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins." *Int. J. Cancer*. 1996 Nov; 68(3): 349-55.

Battelli, M. G., et al. "Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line." *Int. J. Cancer*. 1996 Feb; 65(4): 485-90.

Lee-Huang, S., et al. "Anti-HIV and anti-tumor activities of recombinant MAP 30 from bitter melon." *Gene*. 1995; 161(2):151-56.

Cunnick, J. E., et al. "Induction of tumor cytotoxic immune cells using a protein from the bitter melon (*Momordica charantia*)." *Cell Immunol*. 1990 Apr; 126(2): 278-89.

Zhu, Z. J., et al. "Studies on the active constituents of *Momordica charantia* L." *Yao. Hsueh. Hsueh. Pao*. 1990; 25(12): 898-903.

Stirpe, F., et al. "Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin." *Br. J. Cancer*. 1988 Nov; 58(5): 558-61.

Takemoto, D. J., et al. "Purification and characterization of a cytostatic factor with anti-viral activity from the bitter melon. Part 2." *Prep Biochem*. 1983; 13(5): 397-421.

Takemoto, D. J., et al. "The cytotoxic and cytostatic effects of the bitter melon (*Momordica charantia*) on human lymphocytes." *Toxicon*. 1982; 20: 593-99.

Takemoto, D. J., et al. "Guanylate cyclase activity in human leukemic and normal lymphocytes. Enzyme inhibition and cytotoxicity of plant extracts." *Enzyme*. 1982; 27(3): 179-88.

Takemoto, D. J., et al. "Partial purification and characterization of a guanylate cyclase inhibitor with cytotoxic properties from the bitter melon (*Momordica charantia*)." *Biochem. Biophys. Res. Commun*. 1980; 94(1): 332-39.

Clafin, A. J., et al. "Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (*Momordica charantia* abbreviata)." *Proc. Natl. Acad. Sci*. 1978; 75(2): 989-93.

Vesely, D. L., et al. "Isolation of a guanylate cyclase inhibitor from the balsam pear (*Momordica charantia* abbreviata)." *Biochem. Biophys. Res. Commun*. 1977; 77(4): 1294-99.

### **Vassourinha (*Scoparia dulcis*)**

Kessler, J. H., et al. "Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types." *Cancer Lett*. 2006 Dec 12;

Mukherjee, R., et al. "Betulinic acid derivatives as anticancer agents: structure activity relationship." *Anticancer Agents Med. Chem*. 2006 May; 6(3): 271-9.

Phan, M. G., et al. "Chemical and biological evaluation on scopadulane-type diterpenoids from *Scoparia dulcis* of Vietnamese origin." *Chem. Pharm. Bull*. 2006 Apr; 54(4): 546-9.

Hayashi, K., et al. "The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy." *J. Gene Med*. 2006 Aug; 8(8): 1056-67.

Kasperczyk, H., et al. "Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy." *Oncogene*. 2005 Oct; 24(46): 6945-56.

Fulda, S., et al. "Sensitization for anticancer drug-induced apoptosis by betulinic acid." *Neoplasia*. 2005; 7(2): 162-70.

Garg, A. K., et al. "Chemosensitization and radiosensitization of tumors by plant polyphenols." *Antioxid. Redox. Signal*. 2005; 7(11-12): 1630-47.

Wada, S., et al. "Betulinic acid and its derivatives, potent DNA topoisomerase II inhibitors, from the bark of *Bischofia javanica*." *Chem. Biodivers*. 2005 May; 2(5): 689-94.

Hayashi, K., et al. "Evaluation of scopadulciol-related molecules for their stimulatory effect on the cytotoxicity of acyclovir and ganciclovir against Herpes simplex virus type 1 thymidine kinase gene- transfected HeLa cells." *Chem. Pharm. Bull*. 2004; 52(8): 1015-7.

Ahsan, M., et al. "Cytotoxic diterpenes from *Scoparia dulcis*." *J. Nat. Prod*. 2003; 66(7): 958-61.

Fulda, S., et al. "Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroecto-dermal tumors." *Med. Pediatr. Oncol*. 2000; 35(6): 616-18.

Fulda, S., et al. "Betulinic acid: A new cytotoxic agent against malignant brain-tumor cells." *Int. J. Cancer* 1999; 82(3): 435-41.

Noda, Y., et al. "Enhanced cytotoxicity of some triterpenes toward leukemia L1210 cells cultured in low pH media; possibility of a new mode of cell killing." *Chem. Pharm. Bull*. 1997; 45(10): 1665-70.

Arisawa, M. "Cell growth inhibition of KB cells by plant extracts." *Natural Med*. 1994; 48(4): 338-47.

Nishino, H. "Antitumor-promoting activity of scopadulciol, isolated from the medicinal plant *Scoparia dulcis* L." *Oncology*. 1993; 50(2): 100-3.

Hayashi, T., et al. "Scoparic acid A, a beta-glucuronidase inhibitor from *Scoparia dulcis*." *J. Nat. Prod*. 1992; 55(12): 1748

Hayashi, R. J., et al. "A cytotoxic flavone from *Scoparia dulcis* L." *Chem. Pharm. Bull*. 1988; 36: 4849-51.

### **Mutamba (Guazuma ulmifolia)**

Seigler, D. S. "Cyanogenic glycosides and menisdaurin from *Guazuma ulmifolia*, *Ostrya virginiana*, *Tiquilia plicata* and *Tiquilia canescens*." *Phytochemistry*. 2005 Jul; 66(13): 1567-80.

Ito, H., et al. "Antitumor activity of compounds isolated from leaves of *Eriobotrya japonica*." *J. Agric. Food Chem.* 2002; 50(8): 2400-3.

Kashiwada, Y., et al. "Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents." *J. Nat. Prod.* 1992; 55(8): 1033-43.

Nascimento, S. C., et al. "Antimicrobial and cytotoxic activities in plants from Pernambuco, Brazil." *Fitoterapia*. 1990; 61(4): 353-55.

### **Cat's Claw (Uncaria tomentosa)**

Gonzales, G.F., et al. "Medicinal plants from Peru: a review of plants as potential agents against cancer." *Anticancer Agents Med. Chem.* 2006 Sep; 6(5): 429-44.

De Martino, L., et al. "Proapoptotic effect of *Uncaria tomentosa* extracts." *J. Ethnopharmacol.* 2006 Aug; 107(1): 91-4.

Bacher, N., et al. "Oxindole alkaloids from *Uncaria tomentosa* induce apoptosis in proliferating, G0/G1-arrested and bcl-2-expressing acute lymphoblastic leukaemia cells." *Br. J. Haematol.* 2006 Mar; 132(5): 615-22.

Sheng Y, et al., "Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from *Uncaria tomentosa*." *Phytomedicine*. 2000; 7(2): 137-43.

Riva, L., et al. "The antiproliferative effects of *Uncaria tomentosa* extracts and fractions on the growth of breast cancer cell line." *Anticancer Res.* 2001; 21(4A): 2457-61.

Muhammad, I., et al. "Investigation of Una de Gato I. 7-Deoxyloganic acid and 15N NMR spectroscopic studies on pentacyclic oxindole alkaloids from *Uncaria tomentosa*." *Phytochemistry*. 2001; 57(5): 781-5.

Sheng, Y., et al. "Induction of apoptosis and inhibition of proliferation in human tumor cells treated with extracts of *Uncaria tomentosa*." *Anticancer Res.* 1998; 18(5A): 3363-68.

Salazar, E. L., et al. "Depletion of specific binding sites for estrogen receptor by *Uncaria tomentosa*." *Proc. West. Pharmacol. Soc.* 1998; 41(1): 123-124.

Stuppner, H., et al. "A differential sensitivity of oxindole alkaloids to normal and leukemic cell lines." *Planta Med.* (1993 suppl.); 59: A583.

Rizzi, R., et al. "Mutagenic and antimutagenic activities of *Uncaria tomentosa* and its extracts." *J. Ethnopharmacol.* 1993; 38: 63-77.

Peluso, G., et al. "Effetto antiproliferativo su cellule tumorali di estrattie metaboliti da *Uncaria tomentosa*. Studi in vitro sulla loro azione DNA polimerasi." 11 Congresso Italo-Peruano de Etnomedicina Andina, Lima, Peru, October 27-30, 1993, 21-2.

Rizzi, R., et al. "Bacterial cytotoxicity, mutagenicity and antimutagenicity of *Uncaria tomentosa* and its extracts. Antimutagenic activity of *Uncaria tomentosa* in humans." Premiere Colloque Européan d'Ethnopharmacologie, Metz, France, March 22-24, 1990.

This product is sold through health practitioners, retail stores and [Raintree Nutrition](#). Please contact a health professional concerning other observations and/or effects of this product and/or if you have any disease, condition, or illness for which you are seeking treatment or products for.

**Manufactured By:**  
**Raintree Nutrition, Inc.**  
3579 Hwy 50 East, Suite 222  
Carson City, Nevada 89701  
(800) 780-5902 (775) 841-4142  
[www.RaintreeNutrition.com](http://www.RaintreeNutrition.com)



\* The statements contained herein have not been evaluated by the Food and Drug Administration. This product is not intended to treat, cure, or prevent any disease.